Skip to main content
SpringerLink
Log in

Losartan

A Viewpoint by George Jerums

  • Adis Drug Profile
  • Guest Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 Sep 20; 345(12): 851–60

    Article  PubMed  CAS  Google Scholar 

  2. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23; 359(9311): 1004–10

    Article  PubMed  CAS  Google Scholar 

  3. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993 Nov 11; 329(20): 1456–62

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrinology Unit, Austin & Repatriation Medical Centre, Heidelberg, Australia

    George Jerums

Authors
  1. George Jerums
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jerums, G. Losartan. Drugs 63, 415–416 (2003). https://doi.org/10.2165/00003495-200363040-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200363040-00008

Search

Navigation